Scientific Entertainment

We’re joining the DTS Startup Company Showcase, November 7-10 in Bethesda.

Humaginarium has coined a phrase, “scientific entertainment,” that may be worthy of a trademark. It will depend on the reception it gets from three constituencies: consumers, artists, and scientists.

Consumers may view scientific entertainment as an oxymoron; like something Lewis Carroll uncorked with the mad Hatter. Though television stars like Carl Sagan and Neil deGrasse Tyson have famously made science entertaining, it’s entertaining in a public television sense of the word. In other words, not really. More edifying than fun.

Artists may view scientific entertainment as a dialectic; a juxtaposition of two opposing forces that catalyzes a third force, one that is more than the sum of its parts. Art history is full of examples, wherein monumental aesthetics emerge from a close study of nature; for example in the career of Leonardo da Vinci.

Scientists may view scientific entertainment as… well, I don’t know how they’ll view it! Most likely with grave suspicion because scientists, being truth seekers, are often misunderstood or utterly ignored by masses of people who can’t fathom what they’re up to, or even what they’re talking about. Have you noticed that most scientists portrayed in popular culture are mad? A scientist once pointed that out to me, sardonically.

Humaginarium is going to discover how some scientists view scientific entertainment on November 7-10 in Bethesda, Maryland, at a conference of the Diabetes Technology Society. We’ve been invited to join the DTS Startup Company Showcase, and tell a story about scientific entertainment that may win converts, or cause boredom, or maybe get no reaction whatsoever because we seem unscientific. That last outcome would be the hardest to bear.

To explain what we’re up to, we’ll present our first scientific poster. It will express our mission without any of the eye candy or theatrical heuristics that we employ when pitching. Because we are not going there to pitch. We’ll be there to make a case for scientific entertainment as an incredibly powerful medium for health literacy and education, and scientific acumen among the folk. The poster will describe our startup as though it was an experiment to test a hypothesis that regular folks are not dumb, are not oblivious to their bodies and health, and not incapable of understanding and using erudite scientific concepts so long as the information is reductionist and nicely staged.

In addition to a poster, we’ll hand out a flyer, run a slide show for scientists who want more insight, and conduct dozens of stakeholder interviews. As graduates of I-Corps, that part will be déjà vu all over again!

We hope our experience at the DTS Startup Company Showcase will inspire belief in our idea among the hardest of three constituencies to please. Especially because our prototype and proof of concept is named Diabetes Agonistes. We’ll be putting our hearts on the line, kind of like all scientists do when they’re seeking.

Jacques-Louis_David_Patroclus

Scientific entertainment. Variation on Patroclus, by Jacques-Louis David

Next Steps

In Phase 2 we’ll move fast and break things other than hearts.

A journey of a thousand miles begins with a single step; or in our case a bunch of next steps. We pondered them at the end of August, gave ourselves until the end of December to finish, and got right to work. Here are highlights.

Last week I mentioned the slippery, slimy Business Model Canvas, still wriggling and flipping like a fish out of water. We’re going to reform it yet again, this time after reflecting on what we learned from customer discovery. Ready-aim-fire rather than shoot ourselves in the foot.

We’re going to plan commercialization using Scott Meadow’s model. The practical objective here is to de-risk innovation, a critical success factor in our case because so much of what we do is unfamiliar if not downright unprecedented.

We’re going to qualify business partnerships with Amazon and two medical centers who offered to join us in prototype development. Amazon is intriguing because they’re incredibly exciting; we want to catch their vibe.

We’re going to design a scientific poster for a Startup Company Showcase of the Diabetes Technology Society. (Thanks, Sam!) This is our first chance to pitch the science in our “scientific entertainment” to a community of scientists, a welcome change from geeks of our recent past.

We’re going to write a business pro forma that weighs Humaginarium on the proverbial scales of venture capital. VCs are anything but blind, so we’ll be explicit and transparent. We have a framework but the devil is in the details, waiting for us like Morgoth holed up in Angband.

We’re going to storyboard prototype media: a narrative game simulation that streams to desktops and a casual game that downloads to mobile devices. Both will take on the same chronic illness but in different ways. We want to see which consumers prefer, if not both or neither. Our seed funding will finance production of these digital wonders.

Speaking of seed funding, we’re going to update our website so it says what we say, and write two pitches; one lasting about 10 minutes, the other 30. And now hear this: we will memorize our speaking parts until we can recite them while crossing the Grand Canyon on a tightrope. No more blank stares and stuttering.

Of course we’ll rehearse and refine our pitches with wizards who don’t know what we’re doing; members of the “seen it all, don’t give a shit” investor class that expects mastery of the universe and 30% ROI in five years. Meantime we’ll qualify a list of real prospects for when we’re ready to withstand the inevitable slings and arrows.

Did I mention that we’re going to write a Phase 1 NSF SBIR grant for submission in December? I didn’t because I’m trying to avoid the withering thought, but we shall do this. We’ve already been encouraged by NSF program managers so this milestone is not as far-fetched as it feels. They claim to love moonshots.

In closer proximity to our heart’s desire, we’re going to join MATTER in Chicago. The values of that health tech incubator perfectly match ours; and we want to be active members of the MATTER community. This will be a refreshing change from Polsky and much less of a commute.

We have dubbed these milestones our Phase 2, which officially began on September 1. Not only do we have milestones, we’re writing them into a plan in Project Wizard so that we can move fast and break things other than hearts.

One thing we wanted to do but won’t is use I-Corps Go funds to cover some expenses related to business formation. We’ve already discovered that I-Corps never got the famous memo from the Lords of Business Ethics which says “do what you say you’re going to do.” So when Go fell off the table for no known reason, we were disappointed but not surprised.

In any case I got the memo, many years ago, and have never forgotten it. See the Fellowship page of our website for a nice way of putting it.